Eli Lilly targets alleged black market sales of its experimental GLP-1 drug

Eli Lilly is suing six entitles that it alleges are selling black market versions of its experimental weight loss drug retatrutide.  Lilly’s lawsuits target U.S. entities selling illegal retatrutide products, including compounding pharmacies, medical spas and online sellers that sell retatrutide as a weight-loss “hack.”  Those entities falsely claim their drugs are for “research-use only”…